Jinyu Bio-Technology Co Debt / Assets
Debt-to-Assets Ratio of Jinyu Bio-Technology Co (600201.SS) as of Oct 13, 2026.
Get this data via API
Financial Data API
Debt / Assets
0.00
YoY
504.04%
Last updated:
Debt-to-Assets Ratio of Jinyu Bio-Technology Co is 2024 0.00 . Debt-to-Assets Ratio of Jinyu Bio-Technology Co was 2023 0.00 . It decreases by 504.04% higher compared to the previous year.
The Jinyu Bio-Technology Co Debt / Assets history
3 Years
10 Years
25 Years
Max
Debt / Assets
Date
Debt / Assets
Jan 1, 2017
0.00 CNY
Jan 1, 2018
0.00 CNY
Jan 1, 2019
0.01 CNY
Jan 1, 2020
0.02 CNY
Jan 1, 2021
0.00 CNY
Jan 1, 2022
0.00 CNY
Jan 1, 2023
0.00 CNY
Jan 1, 2024
0.00 CNY
| YEAR | Debt / Assets | YoY |
|---|---|---|
| 0.00 | +504.04% | |
| 0.00 | -76.57% | |
| 0.00 | +1,345.05% | |
| 0.00 | -99.25% | |
| 0.02 | +117.65% | |
| 0.01 | +1,655.77% | |
| 0.00 | -9.97% | |
| 0.00 | +294.72% | |
| 0.00 | -41.34% | |
| 0.00 | -17.73% | |
| 0.00 | — |
Access this data via the Eulerpool API
Jinyu Bio-Technology Co Stock analysis
What does Jinyu Bio-Technology Co do? Jinyu Bio-Technology Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Jinyu Bio-Technology Co stock
On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Jinyu Bio-Technology Co with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
Leverage — Jinyu Bio-Technology Co
All Key Metrics — Jinyu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth